中国生物制药：安罗替尼胶囊+派安普利单抗治肝癌新适应症获受理

Core Viewpoint - China Biologic Products announced positive interim results from a Phase III clinical study of its independently developed Anlotinib hydrochloride capsules combined with Pembrolizumab injection for advanced hepatocellular carcinoma, meeting predefined efficacy standards for progression-free survival (PFS) and overall survival (OS) [1] Group 1: Clinical Study Results - The study included 649 patients with advanced liver cancer [1] - The median PFS for the experimental group was 6.9 months, while the OS was 16.5 months, both significantly better than the control group [1] Group 2: Regulatory Actions - Based on these positive results, the company has applied to the National Medical Products Administration of China for a new indication approval [1] - The new treatment option is expected to provide safer and more convenient choices for patients with advanced hepatocellular carcinoma [1]